



P: +60327277434 E: laboratory@psychology.com.my

WellLab URL: http://malaysialaboratory.com/


## **CIRCULATING TUMOR CELLS (CTC) REPORT**

CTC Test No.	Patient Name	Gender	Age
		Male	53
Patient/Hospital ID.	Physician Name	Hospital	
		NA	
Date of Collection	Date of Sample Receipt	Date of Report	
Medical History			

PATIENT TEST HISTORY

CA Colon

#### RESULT



+ Number of CTCs on which the PD-L1 (22C3) expression was observed

#### **CLINICAL SIGNIFICANCE**

• The OncoDiscover® Circulating Tumor Cell Test is intended for enumeration of Circulating Tumor Cells (CD45-, EpCAM+, PD-L1 and CK8, 18 and 19+) in peripheral blood of epithelial origin cancer patients.<sup>1, 2, 3</sup> Circulating Tumor Cell (CTC) detection at primary diagnosis of cancer predicts an unfavourable prognosis. Presence of CTC post treatment indicates minimal residual disease.<sup>4</sup>

• CTC clusters are defined as a group of two or more aggregated CTCs. Presence of CTC Clusters may be an early indicator of an aggressive metastatic disease.<sup>5</sup> Patient should do a follow-up test upon clinical correlation by the physician.

• PD-L1 expression on CTC is an up- regulated dynamic protein biomarker, whereas PD-L1 expression on tissue is a static snapshot and often not available or adequate. Presence of PD-L1 on CTCs is correlated with a poor prognosis in cancer patients. CPS score of tissuebased PD-L1 is not well co-related with CTC and its PD-L1 expression. However, PD-L1 on CTC is not a standardised diagnostic measure and clinical correlation is advised when interpreting the data.

**APPROVED BY** 

Dr. Amrut Ashturkar M.D. (Pathology) Regd. No. 2003041751


Dr. Javant Khandare **Chief Scientific Officer** 

### DISCLAIMER

The information in this report is meant to be interpreted only by a registered medical professional. The company cannot recommend any therapeutic intervention based on this report. Therapeutic decisions can only be made by a registered medical professional.

4. Pantel et al, Nature Reviews | Clinical Oncology, Vol.16, 2019, 409.

6. Panabieres et al, Clinical Chemistry, 67, 11, 2021, 1503.







Page 1 of 1 Document Format No. FRM/005/05

References

<sup>1.</sup> CDSCO India License No. MFG/IVD/2019/000031

American Society of Clinical Oncology (ASCO) – Journal of Clinical Oncology, 37, No.15, 2019.
Khandare et al, Cancer Res (2023) 83 (7\_Supplement): 6684. AACR 2023.

<sup>5.</sup> Aceto et al, Cell. 2014 Aug 28; 158(5): 1110.

If you have any questions about this report or would like to have a conversation about the test results, please feel free to reach out to us at

03-2727 7434 or laboratory@psychology.com.my

# CONDITIONS OF REPORTING

- 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.
- 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.
- 3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.
- 4. Some tests are referred to other laboratories to provide a wider test menu to the customer.
- 5. CORE Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not attributable to any direct and mala fide act or omission of CORE Diagnostics Pvt. Ltd. or its employees. Liability of CORE Diagnostics Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

